|

Rilvegostomig Clinical Trials

23 actively recruiting trials across 13 locations

Also known as: AZD2936, Other Name: AZD2936

Phoenix, Arizona3 trials

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Research Site

Phase 1/2
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

Research Site

Phase 3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Research Site

Phase 3

Birmingham, Alabama2 trials

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

Research Site

Phase 3
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

Research Site

Phase 2

Anchorage, Alaska2 trials

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

Research Site

Phase 3
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site

Phase 3

Tucson, Arizona2 trials

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site

Phase 3
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Research Site

Phase 3

Los Angeles, California2 trials

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Research Site

Phase 2
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Research Site

Phase 2

Sacramento, California2 trials

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC

UC Davis

Early 1
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies

UC Davis

Early 1

Santa Monica, California2 trials

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

Research Site

Phase 2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

Research Site

Phase 2

Newark, Delaware2 trials

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Research Site

Phase 3
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Research Site

Phase 2

Other1 trial

Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer
Phase 2

Mobile, Alabama1 trial

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

Research Site

Phase 3

Scottsdale, Arizona1 trial

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

Research Site

Phase 3

Little Rock, Arkansas1 trial

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site

Phase 2

Duarte, California1 trial

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Research Site

Phase 1

Grand Rapids, Michigan1 trial

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Research Site

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.